Amgen CEO Bob Bradway announced that new clinical trial data show Repatha significantly reduces heart attack risk by 36% when combined with standard therapies, underscoring the importance of lowering LDL cholesterol for high-risk patients.
#YonhapInfomax #Amgen #Repatha #HeartAttackRisk #LDLCholesterol #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90246